Lu-PNT2002

Lu-PNT2002 is a lutetium-177–labeled, small-molecule radioligand therapy that targets prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). It consists of the beta-emitting radionuclide lutetium-177 chelated to the PSMA-I&T (Imaging & Therapy) peptide, a glutamate-urea–based ligand that binds PSMA on prostate cancer cells, enabling targeted delivery of ionizing radiation that induces DNA damage and tumor cell death while sparing most normal tissues.[1][3] Developed originally at the Technical University of Munich with Scintomics as 177Lu-PSMA-I&T and later advanced clinically by POINT Biopharma/Lantheus, Lu-PNT2002 is being evaluated in phase II–III trials as both systemic mCRPC therapy and as an adjunct to stereotactic body radiotherapy (SBRT) in oligorecurrent, hormone-sensitive prostate cancer, with early data showing favorable dosimetry, manageable hematologic and salivary toxicity, and improved progression-free survival versus androgen receptor pathway inhibitor switches or SBRT alone.[1][2][3][10][11][12][13][14][15]

Brand names

lutetium Lu 177-PNT2002

Other names

Lutetium-177 PNT2002Lutetium177 PNT2002Lutetium 177 PNT2002Lutetium-177 PSMA-I&T